Overview
The Touch® CMC Prosthesis is a dual-mobility implant for the surgical treatment of trapeziometacarpal (CMC) osteoarthritis, the form of arthritis at the base of the thumb most commonly known as rhizarthrosis. The dual-mobility configuration, borrowed from total hip arthroplasty, distributes motion across two articular surfaces and is the principal reason its published dislocation rate sits below 1%. By design the Touch® prosthesis delivers a 116° mobility cone, greater than the native CMC joint, with motion distributed symmetrically when the cup is positioned in the reference orientation.
KeriMedical, the Swiss manufacturer, has built the Touch® system around 144 implant configurations. The combinatorial breakdown is: 6 stem sizes (anatomical trilobe titanium stems with a titanium and hydroxyapatite dual coating), two cup shapes (spherical or conical, in two diameters of 9 mm and 10 mm, stainless steel with the same titanium and hydroxyapatite dual coating), and six neck options (three heights of 6 mm, 8 mm and 10 mm in either straight or 15° offset configurations). The mobile bearing is a highly cross-linked polyethylene (HXLPE) liner with a 4 mm head diameter. The implant is purpose-designed for the trapeziometacarpal joint, not a repurposed hip mini-prosthesis. Touch® is the first CMC1 prosthesis on the market to offer both spherical and conical cup options, and the first dual-mobility CMC1 prosthesis to use a highly cross-linked polyethylene liner.
Touch® is CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015; current MDR certification is valid through 15 February 2028. The implant is GESY-covered in Cyprus when implanted by a participating hand surgeon at a GESY-contracted hospital. (Touch® also holds FDA Premarket Approval P240020, granted 10 July 2025 - relevant as an additional regulatory credential, not a primary positioning point for the Cypriot market.) KeriMedical has been part of the Medartis Group since July 2025 and operates as a distinct hand-and-wrist brand within the group.
OrganoGEN is the exclusive Cyprus distributor and provides surgical support at every implantation.
Indications & Contraindications
Indicated For
- Trapeziometacarpal (CMC) osteoarthritis (rhizarthrosis)
- Painful CMC instability after failed conservative therapy of at least six months
- Post-traumatic CMC arthritis with preserved trapezium height
- Revision of failed trapeziectomy with adequate bone stock
Contraindicated For
- Active local or systemic infection
- Insufficient trapezial bone stock
- Skeletal immaturity
- Patient unable to comply with the post-operative protocol
Technical Specifications
| Manufacturer | KeriMedical SA, Geneva, Switzerland (Medartis Group since July 2025) |
|---|---|
| Configurations | 144 total (6 stems × 4 cup options × 6 neck options) |
| Stem | Titanium, anatomical trilobe section, dual coating (Titanium + hydroxyapatite). 6 sizes (XS, 0, 1, 2, 3, 4) |
| Cups | Stainless steel with dual coating (Titanium + hydroxyapatite). Two shapes (spherical, conical), two diameters (Ø9 mm and Ø10 mm). 4 total cup references |
| Liner | Highly cross-linked polyethylene (HXLPE) |
| Neck and head | Stainless steel. 3 heights (6 mm, 8 mm, 10 mm) in straight or 15° offset configurations. Head diameter 4 mm |
| Articulation | Dual-mobility, 116° mobility cone |
| Regulatory (EU) | CE-marked Class III, EU MDR 2017/745, notified body 2862. Continuously CE-marked since 2015. MDR certification valid through 15 February 2028 |
| Regulatory (US) | FDA PMA P240020, 10 July 2025 |
| Distribution in Cyprus | OrganoGEN Limited (exclusive) |
| GESY reimbursement | Approved (active ZC code) |
Clinical evidence
Single-surgeon comparative series, 184 Touch® prostheses against 168 of the legacy single-mobility Arpe. One dislocation with Touch® (0.5%) against seven with Arpe (4.2%), P=0.02. Overall complication rate 2.7% versus 6.5%. Implant survival 97% at 31 months.
Registry cohort of 125 patients followed to five years. 96% implant survival at 5 years (95% CI 92 to 100). 93% of patients satisfied or very satisfied. Pain, hand function and key-pinch strength all significantly improved from baseline.
Longest published Touch®-specific follow-up. 61 prostheses at a mean of 6.5 years (range 5 to 8.8). Pain fell from 7.3 to 0.4 and key grip strength rose from 67% to 102% of the opposite side. One revision (2%), for cup loosening at seven years. All patients satisfied or very satisfied.
Prospective study of 107 cases with minimum 3-year follow-up. Pain VAS dropped from 7.4 to 0.8 (p<0.001), Kapandji opposition score from 8.0 to 9.4, QuickDASH from 38 to 20 (p<0.01), key-pinch strength from 3.5 kg to 5.5 kg. 95% of patients very satisfied or satisfied. Zero dislocations at minimum 3-year follow-up.
Prospective cohort, 130 patients. 96% implant survival at 2 years (95% CI 90 to 99). Pain at rest fell from 5 to 0 and key-pinch strength rose from 4.5 kg to 7.0 kg. The authors recommend Touch® as the standard procedure for isolated trapeziometacarpal osteoarthritis.
Direct comparison against resection-suspension-interposition arthroplasty. Employed patients returned to work at a mean of 44 days after implant arthroplasty against 84 days after resection. Key-pinch strength 6.8 kg versus 3.1 kg at three months, and 7.0 kg versus 3.9 kg at one year.
Cost-utility analysis over one year, 80 implant patients against 39 resection arthroplasty patients. Implant arthroplasty produced higher quality-adjusted life years (0.89 versus 0.85) at lower total cost (USD 26,809 versus USD 33,953), and stayed cost effective in five-year sensitivity analysis.
Retrospective series of 92 prostheses. No major complications (dislocation, fracture or loosening). Functional QuickDASH scores not significantly different from age-matched general population. Mean return to work 2.6 months.
338 Touch® arthroplasties analysed by cumulative sum method. Surgeons reached proficiency between case 33 and case 40, with mean operating times of 39 to 59 minutes. Two-year outcomes and revision rates were no worse for patients operated before proficiency was reached.
Three-round modified Delphi consensus with 16 hand surgeons and hand therapists from the UK and mainland Europe, setting postoperative best practice and return-to-activity timescales for thumb CMC joint replacement.
French national hospital discharge data, 2009 to 2024, with two surveys of the French Society for Surgery of the Hand. Trapeziometacarpal arthroplasty accounted for 75.1% of all rhizarthrosis procedures in 2024, and the share of surgeons reporting a predominance of arthroplasty rose from 52.5% in 2018 to 85.9% in 2025. A study of the procedure, not of Touch® specifically.
Collects 94 publications and congress abstracts on CMC1 arthroplasty, of which 56 sit in the Touch®-specific sections, covering peer-reviewed clinical series, congress abstracts, comparisons against trapeziectomy, and pre-clinical work. Full bibliography available to qualifying surgeons on request.
Recovery Timeline
| Days 0 to 14 | Immediate protection. A bulky bandage allowing restricted thumb movement, for ten to fourteen days. A post-operative radiograph is taken. |
|---|---|
| Week 2 | Light tasks. Return to light daily tasks at around two weeks. |
| Week 4 | Driving and moderate tasks. Return to driving and to moderate tasks at around four weeks. |
| Weeks 6 to 8 | Heavy tasks. Return to heavy manual tasks at six to eight weeks. Working patients in published series returned to work at a mean of 44 to 51 days. Timings are typical; the operating surgeon sets each patient's programme. |
GESY Coverage & Pricing in Cyprus
The Touch® CMC Prosthesis is GESY-covered under an active ZC code. When implanted by a participating hand surgeon at a GESY-contracted hospital, the device cost is included in the hospital reimbursement, and patients are not billed separately for the implant.
For self-pay or international patients, OrganoGEN provides hospital quotations on request. We do not publish list prices. Request a quote with your hospital's procurement details.
Frequently asked questions
Is the Touch® CMC Prosthesis covered by GESY in Cyprus?
Who manufactures the Touch® CMC Prosthesis?
What is the dislocation rate of the Touch® CMC Prosthesis?
Is the Touch® implant CE-marked?
Why are 144 configurations needed?
What is the polyethylene liner made of and why does it matter?
What functional improvement do patients see after Touch® CMC arthroplasty?
How long does a Touch® CMC prosthesis last?
How soon can patients return to work and normal activities?
How does Touch® compare with trapeziectomy?
Where can patients have Touch® CMC arthroplasty in Cyprus?
More in Hand & Wrist
Other products OrganoGEN distributes in the Hand & Wrist category.
KeriFlex® Finger ImplantMCP and PIP joint arthroplasty implant in high-performance silicone, tested to 10 million flex cycles.
KeriFuse® IP FusionNitinol shape-memory implant for interphalangeal joint fusion, delivering continuous compression across the fusion site.
INTEOS® Distal Radius M4Titanium INTEOS® palmar locking plates for distal radius fracture fixation and corrective osteotomy, by Hofer Medical Solutions, Austria.
XS-INTEOS® MinifragmentTitanium XS-INTEOS® minifragment plates and screws for fixation of small-bone fractures of the hand, by Hofer Medical Solutions, Austria.
OSTYS® Compression Screw 2.8Cannulated titanium compression screw, 2.8 mm thread, by Hofer Medical Solutions, Austria. Hofer's indication: small bones and small bone fragments.












